Cargando…
Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay
The newly developed Axis-Shield clinical chemistry heparin-binding protein (HBP) assay (Axis-Shield Diagnostics Ltd., Dundee, Scotland) can be applied to fully automated platforms. We aimed to establish a reference interval (RI) of HBP using the Axis-Shield HBP assay, and to evaluate the analytical...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406967/ https://www.ncbi.nlm.nih.gov/pubmed/36010280 http://dx.doi.org/10.3390/diagnostics12081930 |
_version_ | 1784774250790387712 |
---|---|
author | Yoon, Sumi Hur, Mina Kim, Hanah Moon, Hee-Won Yun, Yeo-Min |
author_facet | Yoon, Sumi Hur, Mina Kim, Hanah Moon, Hee-Won Yun, Yeo-Min |
author_sort | Yoon, Sumi |
collection | PubMed |
description | The newly developed Axis-Shield clinical chemistry heparin-binding protein (HBP) assay (Axis-Shield Diagnostics Ltd., Dundee, Scotland) can be applied to fully automated platforms. We aimed to establish a reference interval (RI) of HBP using the Axis-Shield HBP assay, and to evaluate the analytical performance of this assay. An RI was established in 212 sodium citrated plasma samples using the non-parametric method (2.5th and 97.5th percentiles). Precision, linearity, and carry-over were evaluated according to the Clinical and Laboratory Standards Institute guidelines. The RI of HBP was between 5.3 ng/mL and 171.0 ng/mL, which could be applied regardless of gender and age. Percentage coefficients of variations (%CVs) of repeatability and within-laboratory precision were 4.9% and 6.3%, respectively, for low-concentration control and 1.6% and 3.0%, respectively, for high-concentration control. The linearity was excellent (coefficient of determination (R(2)) = 0.99), and the carry-over rate was negligible (0.05%). This is the first study to establish an RI of HBP using the newly developed and fully automated Axis-Shield HBP assay. The Axis-Shield HBP assay showed an acceptable level of analytical performance and could be used to measure HBP concentrations effectively in routine clinical practice. Further studies are awaited to evaluate the clinical utility of HBP using this automated assay. |
format | Online Article Text |
id | pubmed-9406967 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94069672022-08-26 Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay Yoon, Sumi Hur, Mina Kim, Hanah Moon, Hee-Won Yun, Yeo-Min Diagnostics (Basel) Article The newly developed Axis-Shield clinical chemistry heparin-binding protein (HBP) assay (Axis-Shield Diagnostics Ltd., Dundee, Scotland) can be applied to fully automated platforms. We aimed to establish a reference interval (RI) of HBP using the Axis-Shield HBP assay, and to evaluate the analytical performance of this assay. An RI was established in 212 sodium citrated plasma samples using the non-parametric method (2.5th and 97.5th percentiles). Precision, linearity, and carry-over were evaluated according to the Clinical and Laboratory Standards Institute guidelines. The RI of HBP was between 5.3 ng/mL and 171.0 ng/mL, which could be applied regardless of gender and age. Percentage coefficients of variations (%CVs) of repeatability and within-laboratory precision were 4.9% and 6.3%, respectively, for low-concentration control and 1.6% and 3.0%, respectively, for high-concentration control. The linearity was excellent (coefficient of determination (R(2)) = 0.99), and the carry-over rate was negligible (0.05%). This is the first study to establish an RI of HBP using the newly developed and fully automated Axis-Shield HBP assay. The Axis-Shield HBP assay showed an acceptable level of analytical performance and could be used to measure HBP concentrations effectively in routine clinical practice. Further studies are awaited to evaluate the clinical utility of HBP using this automated assay. MDPI 2022-08-10 /pmc/articles/PMC9406967/ /pubmed/36010280 http://dx.doi.org/10.3390/diagnostics12081930 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yoon, Sumi Hur, Mina Kim, Hanah Moon, Hee-Won Yun, Yeo-Min Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay |
title | Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay |
title_full | Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay |
title_fullStr | Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay |
title_full_unstemmed | Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay |
title_short | Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay |
title_sort | reference interval for the axis-shield clinical chemistry heparin-binding protein assay |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406967/ https://www.ncbi.nlm.nih.gov/pubmed/36010280 http://dx.doi.org/10.3390/diagnostics12081930 |
work_keys_str_mv | AT yoonsumi referenceintervalfortheaxisshieldclinicalchemistryheparinbindingproteinassay AT hurmina referenceintervalfortheaxisshieldclinicalchemistryheparinbindingproteinassay AT kimhanah referenceintervalfortheaxisshieldclinicalchemistryheparinbindingproteinassay AT moonheewon referenceintervalfortheaxisshieldclinicalchemistryheparinbindingproteinassay AT yunyeomin referenceintervalfortheaxisshieldclinicalchemistryheparinbindingproteinassay |